Vision Capital Advisors

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Meru Networks specializes in the development and marketing of wireless LAN infrastructure solutions that utilize virtualization to provide reliable and high-quality wireless service essential for business-critical applications, including voice, video, and data. Since its establishment, the company has pioneered its innovative virtual cell wireless architecture, which significantly departs from traditional hub-based WLAN systems. Meru's products are designed to deliver performance, reliability, security, and cost-effectiveness comparable to that of wired networking, making them suitable for enterprises seeking robust wireless solutions.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for treating various cancers, both hematologic and solid. Its lead candidate, vecabrutinib, is a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also advancing SNS-510, which is in preclinical studies for solid tumors and hematologic malignancies. Additionally, Sunesis is involved in partnered programs, including TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer agent that affects DNA and inhibits topoisomerase II. Collaborative efforts with Biogen Idec and Takeda Pharmaceutical focus on developing small molecule BTK inhibitors and preclinical PDK1 inhibitors, respectively. Founded in 1998, Sunesis Pharmaceuticals is headquartered in South San Francisco, California.

OnlineSheetMusic is a licensed Internet-based digital sheet music stores. OSM offers nearly 140,000 pieces of digital sheet music and guitar tablature, many transposable instantly using its Solero software. Its titles are obtained from scores of publishers including: Alfred Music Publishing, Sony/ATV Music Publishing, Universal Music Publishing, EMI Music Publishing, BMG, Peer Music Publishing, and Disney Music Publishing.

MetricStream, Inc. is a leading provider of governance, risk, and compliance (GRC) software solutions, offering both cloud-based and on-premise applications. Founded in 1999 and headquartered in Palo Alto, California, the company serves a diverse range of industries, including banking, healthcare, automotive, and energy. Its software platform encompasses various functions such as internal audits, regulatory compliance, risk management, quality assurance, and vendor governance, enabling organizations to enhance their business performance and make informed decisions amidst regulatory complexities. MetricStream's solutions facilitate the integration of governance, risk management, and compliance across organizations, empowering users to navigate risks effectively while pursuing growth opportunities. With a commitment to customer support, implementation, and training, MetricStream continues to strengthen its presence in the global market through strategic partnerships and a robust portfolio of services.